We subjected our individual phosphoproteomic data of HER2-positive gastric cancer to kinase-substrate enrichment analysis (KSEA) to identify active kinases after drug therapy in a personalized manner (Fig. 6, Table S8). Here, ERBB2 is linked to gastric cancer.